Christopher R. Flowers, MD, ACTSI investigator, associate professor, Department of Hematology and Medical Oncology, Emory University School of Medicine, and director, Emory Lymphoma Program, Winship Cancer Institute
Science Daily | New Drug Shows Promise in Treating Indolent Non-Hodgkin Lymphomas
January 22, 2014
Flowers is PI on the trial PCI-32765DBL3001: A Randomized, Double-blind, Placebo-controlled Phase III Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, PCI-32765 (Ibrutinib), in Combination with Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Subjects With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma
US News & World Report | Columbus Dispatch | Englemed Health News | Live Sicence | Science Codex| Central Valley Business Times | Daily Rx | Innovations Report| Mapping a link between blood cancer, industrial pollutant in Georgia
July 29, 2013
Medical News Today | African Americans with blood cancer do not live as long as caucasians, despite equal care
July 8, 2013
Herald Online.com| CLL diagnosis and treatment update
August 23, 2012